Laurus Labs Allots 62,635 Shares Under ESOP Schemes
Laurus Labs allotted 62,635 equity shares to 839 employees on July 27, 2026, under its ESOP schemes. The allotment was made under the 2016, 2018, and 2021 ESOP schemes. The total paid-up capital now stands at Rs. 1,08,06,24,436.
The allotment of shares under ESOPs is a regular occurrence and the number of shares allotted is a small fraction of the total outstanding shares. Therefore, the impact on the company's overall financial health or market valuation is minimal.
The announcement pertains to the routine allotment of shares under employee stock option plans, which is a standard corporate practice and does not significantly impact the company's financial performance or stock price.
Laurus Labs Limited announced the allotment of 62,635 equity shares of Rs. 2 each, fully paid up, to eligible employees on the exercise of their stock options. This allotment was made on July 27, 2026, pursuant to resolutions passed by circulation by the Nomination & Remuneration Committee of the Directors.
The allotment was made under three different schemes: Laurus Employees Stock Option Scheme 2016 (Grant IV), Laurus Employees Stock Option Scheme 2018 (Grant IV), and Laurus Labs Employees Stock Option Scheme 2021 (Grant II). A total of 839 employees were involved in this exercise.
Under the Laurus Employees Stock Option Scheme 2016 (Grant IV), 435 shares were allotted with an exercise price of Rs. 301.50 per share, realizing Rs. 1,31,152.50. For the Laurus Employees Stock Option Scheme 2018 (Grant IV), 47,528 shares were allotted at an exercise price of Rs. 463.50 per share, generating Rs. 2,20,29,228. Under the Laurus Labs Employees Stock Option Scheme 2021 (Grant II), 14,672 shares were allotted at an exercise price of Rs. 463.50 per share, realizing Rs. 68,00,472.
The total amount realized from the exercise of these options is Rs. 2,89,60,852.50. Following this allotment, the company's total paid-up capital stands at Rs. 1,08,06,24,436, divided into 54,03,12,218 equity shares of Rs. 2 each. The company has provided detailed disclosures as required by SEBI regulations.
What to do with a filing like this
Laurus Labs Limited filed this with the NSE as a statutory disclosure, categorised under shareholding pattern. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Laurus Labs Limited. Read the original for the full detail.